Am J Health-Syst Pharm
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


American Journal of Health-System Pharmacy, Vol. 62, Issue 11, 1159-1170
Copyright © 2005 by American Society of Health-System Pharmacists
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rivkin, K.
Right arrow Articles by Lyakhovetskiy, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rivkin, K.
Right arrow Articles by Lyakhovetskiy, A.

Therapy Updates

Treatment of nonvariceal upper gastrointestinal bleeding

Kirill Rivkin and Aleksandr Lyakhovetskiy

KIRILL RIVKIN, PHARM.D., BCPS, is Clinical Pharmacy Specialist, and ALEKSANDR LYAKHOVETSKIY, PHARM.D., BCPS, is Clinical Pharmacy Specialist, Lincoln Medical and Mental Center, Bronx, NY.

Address correspondence to Dr. Rivkin at Lincoln Medical Center, 234 East 149 Street, Bronx, NY 10451 (kirfa{at}hotmail.com).


Purpose. The etiology, pathophysiology, prognostic factors, pharmacologic treatment, and pharmacoeconomic considerations of nonvariceal upper-gastrointestinal-tract bleeding (UGB) are reviewed.

Summary. UGB is associated with substantial morbidity and mortality. While UGB can be caused by a wide variety of medical conditions, 50% of UGB cases are caused by peptic ulcers. Approximately 80% of all UGB episodes stop bleeding spontaneously. Recurrence of gastrointestinal hemorrhage is associated with an increased mortality rate, a greater need for surgery, blood transfusions, a prolonged length of hospital stay, and increased overall health care costs. All patients with UGB should be evaluated for signs and symptoms of hemodynamic instability and active hemorrhage. Endoscopy within the first 24 hours of a UGB episode is considered the standard of therapy for the management of the initial hemorrhage. However, approximately 20% of patients will experience a rebleeding episode. Acid-suppressive therapy with proton-pump inhibitors (PPIs) in addition to endoscopic hemostasis is effective in reducing the frequency of rebleeding, the need for surgery, transfusion requirements, and the length of hospital stay, but not mortality rates. There are multiple dosing options for administration of PPIs in this setting. More studies are necessary to elucidate the best therapeutic approach to manage UGB.

Conclusion. Acid-suppressive therapy is beneficial in the management of UGB. It reduces the frequency of rebleeding, the need for surgery, transfusion requirements, and the length of hospital stay. To date, no pharmacologic intervention has demonstrated a reduction in the mortality rates of patients with UGB. An optimal acid-suppressive regimen has not yet been clearly established.

Index terms: Blood; Costs; Dosage; Gastrointestinal drugs; Gastrointestinal hemorrhage; Hospitals; Mortality; Pharmacoeconomics; Surgery

 



This article has been cited by other articles:


Home page
CirculationHome page
N. G. Vallurupalli and S. Z. Goldhaber
Gastrointestinal Complications of Dual Antiplatelet Therapy
Circulation, March 28, 2006; 113(12): e655 - e658.
[Full Text] [PDF]


Home page
Am J Health Syst PharmHome page
H. Cohen and J. A. Rebuck
Proton-pump inhibitors for upper-gastrointestinal bleeding
Am. J. Health Syst. Pharm., February 1, 2006; 63(3): 214 - 216.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 by the American Society of Health-System Pharmacists.